First-line brentuximab vedotin plus chemotherapy improves overall survival in patients with stage III/ IV classical Hodgkin Lymphoma: an updated analysis of ECHELON-1
Straus, D. Connors, J. Kim, W. S. Gallamini, A. Ramchandren, R. Friedberg, J. Advani, R. Hutchings, M. Evens, A.
Straus, D.
Connors, J.
Kim, W. S.
Gallamini, A.
Ramchandren, R.
Friedberg, J.
Advani, R.
Hutchings, M.
Evens, A.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Straus D, Radford J, Connors J, Kim WS, Gallamini A, Ramchandren R, et al. First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/ IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1. Clinical Lymphoma Myeloma & Leukemia. 2022 Oct;22:S350-S. PubMed PMID: WOS:000897948100362.